Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 M versus AMINOSYN II 8 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 M versus AMINOSYN II 8 5 W ELECTROLYTES.
AMINOSYN 3.5% M vs AMINOSYN II 8.5% W/ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% M is a crystalline amino acid solution providing essential and nonessential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance. It acts as a substrate for anabolic processes and helps correct negative nitrogen balance.
Amino acids serve as substrates for protein synthesis and provide nitrogen for metabolic processes. Electrolytes maintain acid-base balance and osmotic pressure.
Intravenous infusion; typical adult dose: 1 to 1.5 g amino acids/kg/day (equivalent to 28.6 to 42.9 mL/kg/day of 3.5% solution). Administer via central or peripheral line at a rate not exceeding 0.5 g amino acids/kg/hour.
1 to 1.5 g amino acids/kg/day intravenously, typically infused over 12-24 hours.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is typically 0.5-2 hours in patients with normal renal and metabolic function, reflecting rapid uptake and metabolism by tissues. In hepatic or renal impairment, half-life may be prolonged due to decreased clearance.
Variable; amino acids typically have half-lives of minutes to hours; free amino acids in plasma have t1/2 of 10-30 minutes for most
Amino acids in Aminosyn 3.5% M are primarily eliminated via metabolism (utilization for protein synthesis, energy, and other metabolic pathways). Minimal amounts are excreted unchanged in urine (less than 5% of infused amino acids) via glomerular filtration. There is no significant biliary or fecal elimination.
Renal >90% (as amino acids and metabolites); fecal <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution